Other United States Food and Drug Administration (FDA) approved anti-cancer drugs that are studied to target c-kit include Amuvatinib, which has been clinically tested for lymphoma and small cell lung carcinomas, Axitinib, was clinically tested for advanced renal cell carcinoma, Cabozantinib, for prostate cancers and Dasatinib, for Chronic myeloid leukemia (52). Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.